IEX •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization5.98 mln
Float1.25 mln
Earnings Date08/06/2026
EPS
1,488
Exceptional
P / E
0.00
Anomalous
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
25.50
Transformational upside
Relative Strength
19
/ 100
Significantly lagging
Debt / Equity
0.38
Low leverage
Business Description
Aptevo Therapeutics is a Seattle-based biotechnology company focused on developing new treatments for cancer by harnessing the body's own immune system. Founded in 2016, the company uses its proprietary platforms to create a range of antibody-based therapies targeting blood cancers and solid tumors. Its most advanced treatment candidate is currently in mid-stage clinical trials for acute myelogenous leukemia, while several other candidates are being tested or studied across a wide variety of cancer types. The company also works with external partners to advance select programs through the development pipeline.
